Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas.
J Clin Oncol
; 14(1): 25-34, 1996 Jan.
Article
in En
| MEDLINE
| ID: mdl-8558206
ABSTRACT
PURPOSE:
In contrast to other human tumors, a repression of the cell-surface glycoprotein CD44 on neuroblastoma is a marker of aggressiveness that usually correlates to N-myc amplification. We thus compared the prognostic value of both markers in the initial staging of 121 children treated for neuroblastoma in collaborative institutions.METHODS:
Frozen samples were analyzed by a rapid and well-standardized technique of immunostaining with monoclonal antibodies (MoAbs) against epitopes in the CD44 constant region.RESULTS:
In this retrospective series, CD44 was expressed on 102 specimens and strongly correlated with favorable tumor stages and histology, younger age, and normal N-myc copy numbers. In univariate analysis, CD44 expression and normal N-myc were the most powerful markers of favorable clinical outcome (P < 10(-6) and chi 2 = 65.40 and P < 10(-6) and chi 2 = 42.56, respectively), but analysis of CD44 affords significant prognostic discrimination in subgroups of patients with or without N-myc-amplified tumors. In the subgroup of stage IV neuroblastomas, CD44 was the only significant prognostic marker (P < .02, chi 2 = 5.76), whereas N-myc status was not discriminant. In multivariate analysis of five factors, ie, N-myc amplification, CD44 expression, age, tumor stage, and histology, the only independent prognostic factors of event-free survival were CD44 expression and tumor stage.CONCLUSION:
The analysis of CD44 cell-surface expression must be recommended as an additional biologic marker in the initial staging of the disease.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Biomarkers, Tumor
/
Genes, myc
/
Hyaluronan Receptors
/
Neuroblastoma
Type of study:
Observational_studies
/
Prognostic_studies
Limits:
Female
/
Humans
/
Infant
/
Male
Language:
En
Journal:
J Clin Oncol
Year:
1996
Type:
Article
Affiliation country:
France